AB115805

Anti-VEGF Receptor 2 抗体 [SP123]

Name: Anti-VEGF Receptor 2 抗体 [SP123] (ab115805) | Abcam
Brand: Abcam Limited
SKU: AB115805
Price: 30000 JPY
Availability: InStock
Rating: 5 (3 reviews)

Anti-VEGF Receptor 2 antibody [SP123]

20ul selling size
RabMAb
Recombinant
詳細を見る

(3 Reviews)

(14 Publications)

Rabbit Recombinant Monoclonal VEGF Receptor 2 antibody. Suitable for IHC-P and reacts with Human samples. Cited in 14 publications.

別名を表示する

CD309, FLK1, VEGFR2, KDR, Vascular endothelial growth factor receptor 2, VEGFR-2, Fetal liver kinase 1, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1, FLK-1

3 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 2 antibody [SP123] (AB115805)

IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 2 antibody [SP123] (AB115805)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human glioma tissue sections labeling VEGF Receptor 2 with ab115805 at 1/100 dilution (1.72 µg/ml). Heat mediated antigen retrieval was performed Heat mediated antigen retrieval with sodium citrate buffer (pH 6.0, epitope retrieval solution 1) for 10 mins. Rabbit specific IHC polymer detection kit HRP/DAB (ab209101) was used as the secondary antibody. Negative control : PBS instead of the primary antibody. Hematoxylin was used as a counterstain.

IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 2 antibody [SP123] (AB115805)

Staining of Human VEGF Receptor 2 in a Formalin/PFA-fixed paraffin-embedded section of Human Placenta using ab115805 at a dilution of 1/100.

IHC-P

AbReview77521****

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 2 antibody [SP123] (AB115805)

Immunohistochemistry analysis (Formalin/PFA-fixed paraffin-embedded sections) of paraformaldehyde fixed, 1% TritonX-100 in PBS permeabilized human Metastatic melanoma tissue. Stained with ab115805 at 1/200 dilution. Secondary antibody used was HRP Donkey Jackson Immuno Anti-rabbit at 1/500 dilution. Blocking was done with 3% donkey serum for 30 minutes at 25°C. The sample was incubated with the primary antibody and 1% donkey serum for 1 hour at 25°C. Antigen retrieval method was heat mediated Tris-EDTA

This image is courtesy of an Abreview submitted by Daniel Kirsch

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

SP123

アイソタイプ

IgG

キャリアフリー

交差種

Human

アプリケーション

IHC-P

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100", "IHCP-species-notes": "<p></p>" }, "Mouse": { "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }

style

left-column

製品の詳細

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

出荷温度及び保存条件

製品の状態

Liquid

精製方法

Affinity purification Protein A/G

精製に関する特記事項

Purified from TCS by protein A/G.

バッファー組成

pH: 7.6 Preservative: 0.1% Sodium azide Constituents: PBS, 1% BSA

出荷温度

Blue Ice

短期保存温度

+4°C

長期保存温度

-20°C

分注に関する情報

Upon delivery aliquot

保管に関する情報

Avoid freeze / thaw cycle

style

left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

VEGF Receptor 2 also known as KDR or Flk-1 is a receptor tyrosine kinase important for mediating the effects of vascular endothelial growth factor (VEGF). This protein has a mass of approximately 150 kDa. It mostly expresses in vascular endothelial cells playing a primary role in the formation of blood vessels. The receptor can also be found in various non-endothelial tissues though in smaller amounts indicating its broad functional roles outside of the vascular system.

Biological function summary

VEGF Receptor 2 is important for angiogenesis and vascular permeability. It is part of the VEGF receptor family which also includes VEGF Receptors 1 and 3 forming a complex interaction network. Upon binding with VEGF it phosphorylates key proteins to initiate signals that regulate endothelial cell migration proliferation and survival. The receptor's function is critical for normal developmental processes and wound healing as well.

Pathways

VEGF Receptor 2 is especially important within the angiogenesis and vascular permeability pathways. It plays a central role in the VEGF signaling pathway alongside proteins like VEGF A which is the primary ligand for the receptor. The signaling through this receptor modulates various downstream proteins through phosphorylation linking it to pathways that control cellular responses essential for blood vessel formation and maintenance.

VEGF Receptor 2 is significantly linked with cancer and age-related macular degeneration. In the context of cancer the overexpression or dysregulation of VEGF and its receptors including VEGF Receptor 2 often leads to enhanced tumor angiogenesis promoting tumor growth and metastasis. Additionally the receptor interacts with other proteins in pathological states such as CD309 in endothelial cell-based assays which are used for research like flow cytometry and ELISA to monitor VEGF Receptor 2 activity and its impact on diseases.

style

left-column

style

left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

ターゲットの情報

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

See full target information KDR

style

left-column

文献 (14)

Recent publications for all applications. Explore the full list and refine your search

Drug target insights 19:59-70 PubMed40917740

2025

The Bushenhuoxue formula improves prothrombotic state in recurrent spontaneous abortion: network pharmacology and experimental validation.

Applications

Unspecified application

Species

Unspecified reactive species

Xuan Yang,Shulan Su,Lijing Liu,Pan Liu,Maoqing Lu,Yinuo Wei,Yaqiong Gao

Anticancer research 45:639-650 PubMed39890197

2025

Efficacy of Second-line Nivolumab Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases.

Applications

Unspecified application

Species

Unspecified reactive species

Gaku Yamamichi,Taigo Kato,Akihiro Yoshimura,Masaru Tani,Yuki Horibe,Yutong Liu,Nesrine Sassi,Yohei Okuda,Toshiki Oka,Toshihiro Uemura,Akinaru Yamamoto,Y U Ishizuya,Takuji Hayashi,Yoshiyuki Yamamoto,Koji Hatano,Atsunari Kawashima,Tetsuya Takao,Kensaku Nishimura,Shingo Takada,Masao Tsujihata,Norio Nonomura

Journal of inflammation research 17:8945-8964 PubMed39588137

2024

Early-Life Stress Induced by Neonatal Maternal Separation Leads to Intestinal 5-HT Accumulation and Causes Intestinal Dysfunction.

Applications

Unspecified application

Species

Unspecified reactive species

Ding Yang,Rulan Bai,Chengzhong Li,Yan Sun,Hongyu Jing,Zixu Wang,Yaoxing Chen,Yulan Dong

Molecular therapy. Nucleic acids 35:102322 PubMed39363882

2024

Highly efficient nucleic acid encapsulation method for targeted gene therapy using antibody conjugation system.

Applications

Unspecified application

Species

Unspecified reactive species

Seokbong Hong,Seung-Hwan Jeong,Jang Hee Han,Hyeong Dong Yuk,Chang Wook Jeong,Ja Hyeon Ku,Cheol Kwak

The Tohoku journal of experimental medicine 264:141-149 PubMed38925952

2024

The Prognostic Significance of Transient Receptor Potential Canonical 1 and Its Association with Vascular Endothelial Growth Factor Receptor 2 in Papillary Thyroid Carcinoma Patients.

Applications

Unspecified application

Species

Unspecified reactive species

Mengshi Chen,Bo Liu,Zhaoming Ding,Ruinan Sheng,Jiewu Zhang

Frontiers in immunology 14:1298418 PubMed38239359

2024

Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.

Applications

Unspecified application

Species

Unspecified reactive species

Yunyan Mo,Yufei Pan,Bin Zhang,Jian Zhang,Yixin Su,Zhengchun Liu,Meiqing Luo,Guanjie Qin,Xiangyun Kong,Rongjun Zhang,Yu Pan,Yi Liang,Defeng Wang,Yuejia Wei,Hengwei Chen,Wei Jiang

Frontiers in nutrition 10:1221935 PubMed37876615

2023

Short term effect of tetrahydrocurcumin on adipose angiogenesis in very high-fat diet-induced obesity mouse model.

Applications

Unspecified application

Species

Unspecified reactive species

Bhornprom Yoysungnoen,Umarat Srisawat,Pritsana Piyabhan,Naphatsanan Duansak,Nattapon Sookprasert,Nakorn Mathuradavong,Natwadee Poomipark,Narongsuk Munkong,Pholawat Tingpej,Chatchawan Changtam

Computational and mathematical methods in medicine 2022:7214904 PubMed36276991

2022

Apatinib Functioned as Tumor Suppressor of Synovial Sarcoma through Regulating miR-34a-5p/HOXA13 Axis.

Applications

Unspecified application

Species

Unspecified reactive species

Qi Feng,Donglai Wang,Peng Guo,Zibo Zhang,Jiangang Feng

Regenerative biomaterials 9:rbac033 PubMed35719204

2022

Three-dimensional-printed polycaprolactone scaffolds with interconnected hollow-pipe structures for enhanced bone regeneration.

Applications

Unspecified application

Species

Unspecified reactive species

Jiahua Duan,Dong Lei,Chen Ling,Yufeng Wang,Zhicheng Cao,Ming Zhang,Huikang Zhang,Zhengwei You,Qingqiang Yao

Frontiers in pharmacology 12:656115 PubMed34276360

2021

Network Pharmacological Analysis and Experimental Validation of the Mechanisms of Action of Si-Ni-San Against Liver Fibrosis.

Applications

Unspecified application

Species

Unspecified reactive species

Siliang Wang,Cheng Tang,Heng Zhao,Peiliang Shen,Chao Lin,Yun Zhu,Dan Han

View all publications

style

left-column

style

left-column

style

right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。

保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-VEGF Receptor 2 抗体 [SP123]

Anti-VEGF Receptor 2 antibody [SP123]

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 2 antibody [SP123] (AB115805)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 2 antibody [SP123] (AB115805)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 2 antibody [SP123] (AB115805)

関連する標識済み抗体及び組成の異なる製品 (8)

Key facts

宿主種

クローン性

クローン番号

アイソタイプ

キャリアフリー

交差種

アプリケーション

免疫原

Reactivity data

製品の詳細

出荷温度及び保存条件

製品の状態

精製方法

精製に関する特記事項

バッファー組成

出荷温度

短期保存温度

長期保存温度

分注に関する情報

保管に関する情報

補足情報

Biological function summary

Pathways

製品プロトコール

ターゲットの情報

文献 (14)

代替製品

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

組合せ製品

Assay Kits

Primary Antibodies

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Abcam product promise